Both CD133 and ALDH as markers can be used to identify dual-positive HCC cells, which may serve as a cell model to understand HCC carcinogenesis and to identify and select new therapeutic targets through molecular, genomic, and epigenetic analyses 106, 107. This evidence concerns the gene LDHA and hepatocellular carcinoma.